• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Regulatory press release

2cureX AB Expands Functional Precision Medicine Infrastructure Through Strategic Collaboration with StoreMyTumor

2cureX
Download the release

2cureX AB today announces the signing of a strategic services and collaboration agreement with StoreMyTumor, a US-based oncology logistics and tumour preservation platform operating under AAA Health Solutions.

The agreement supports the continued expansion of 2cureX AB’s broader Functional Precision Medicine infrastructure, including patient access pathways, tumour collection coordination, cryopreservation logistics, and future integration opportunities across decentralised oncology testing workflows.

The collaboration is intended to strengthen operational connectivity between patients, clinics, laboratories, and future testing platforms, supporting the company’s broader ecosystem strategy within precision oncology.

StoreMyTumor’s tumour preservation and logistics capabilities may also support future applications connected to 2cureX AB’s developing TwinCode strategy and broader data-driven oncology initiatives.

“This collaboration represents another important step in the continued development of our broader Functional Precision Medicine infrastructure,” said Nat Hutley, CEO of 2cureX AB. “We believe the future of precision oncology will increasingly depend on operational coordination, patient access, and scalable ecosystem partnerships alongside testing technologies themselves.”

The agreement is expected to support future commercial and operational opportunities within both European and US precision oncology markets.

For more information about 2cureX:


Nathaniel Hutley, Interim CEO
E-mail: NH@2curex.com
Telephone: +44 (776) 514 1346

About 2cureX


2cureX is redefining cancer treatment selection through functional precision oncology. Its proprietary IndiTreat® test family creates thousands of 3D tumor replicas—called tumoroids—from a patient’s biopsy to identify which chemotherapy or targeted drugs that are most effective for that specific tumor. The result: real data to drive real decisions.
The first three IndiTreat® tests target patients with metastatic colorectal cancer:
                •  IndiTreat® Start (first-line therapy)
                •  IndiTreat® Extend & Explore (third-line options)
 
New IndiTreat® versions are in development for earlier-stage colorectal cancer and other GI cancers.
Despite global cancer IVD spending exceeding $17.5 billion annually, fewer than 1 in 3 treatments are guided by a predictive test. IndiTreat® aims to close that gap—bringing clarity to treatment selection and precision to every patient.
 
2cureX AB is listed on Nasdaq First North Growth Market under the ticker 2CUREX, with operational delivery in partnership with 2cureX A/S in Denmark. This cross-border structure powers the company’s new commercial strategy, Operation Twin Code—now live.

This information is information that 2cureX is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-05-20 16:45 CEST.

Attachments


2cureX AB Expands Functional Precision Medicine Infrastructure Through Strategic Collaboration with StoreMyTumor